Clinical Trials on Glabellar Crease

Total 10000 results

‹
1
2
...
38
39
40
41
42
43
44
...
199
200
›

Shu Wang

Recruiting

Chemotherapy Combined With Targeted Therapy for High-risk HER2 Positive and Lymph Node Negative Early Breast Cancer (TaxCbHER2)

HER2-positive Breast Cancer

China
Shu Wang

Recruiting

Adjuvant Therapy for Intermediate Risk HER2 Positive, Lymph Node Negative Early Breast Cancer With Chemotherapy Combined Target Therapy (TaxDHER2)

HER2-positive Breast Cancer

China
Lamiaa Gomaa Ahmed Elsayed

Not yet recruiting

Role of MRI in Breast Cancer Subtypes (MRI)

MRI in Breast Cancer
European Institute of Oncology

Recruiting

Analysis of Circulating Tumor DNA (ctDNA) in HER2-low Advanced/Metastatic Breast Cancer (LEGO)

Advanced Metastatic Breast Cancer

Italy
Fudan University

Not yet recruiting

T-DXd Versus THP for Medium-risk HER2-positive Early Breast Cancer

HER2-positive Breast Cancer

China
Gadjah Mada University
Pfizer; Queensland University of Technology

Not yet recruiting

Collaborative cOMMUNIty Care for Metastatic breAsT cancEr Patients in inDonesia (Communicated) (Communicated)

Cancer | Metastatic Breast Cancer

Indonesia
Centre Jean Perrin

Recruiting

Augmented Reality Feasibility for Non-invasive Preoperative Tracking in Breast Cancer Surgery (AR-GBS)

Subclinical Breast Cancer Lesion

France
Assiut University

Not yet recruiting

Predicting Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer

Locally Advanced Breast Cancer
KARANAHAN

Recruiting

Clinical Study of Personalized Chemotherapy for Breast Cancer With Low Doses of Cyclophosphamide

Stage IV Breast Cancer

Russian Federation
Samsung Medical Center

Recruiting

The Resistance Mechanism of Trastuzumab Deruxtexan in HER2 Positive Breast Cancer Patients.

HER2-positive Breast Cancer

Korea, Republic of
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer

HER2-positive Breast Cancer

China
SOLTI Breast Cancer Research Group

Recruiting

HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan (ACROSS-TROP2)

Breast Cancer Stage IV

Spain
Shanghai Yizhong Pharmaceutical Co., Ltd.

Recruiting

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

Metastatic Breast Cancer (MBC)

China
Huashan Hospital

Recruiting

Study of 68Ga /131I SGMIB-ZT-199 PET Imaging Targeting HER2-positive in the Diagnosis of Metastatic Breast Cancer

HER2-positive Breast Cancer

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Trial of Eribulin in Combination With HP Neoadjuvant Therapy in Patients With for HER2-Positive BC

HER2-positive Breast Cancer

China
Henan Cancer Hospital

Recruiting

A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer

HER2 Low Breast Carcinoma

China
Fudan University

Not yet recruiting

A Randomized, Controlled, Open-label Clinical Trial of Adjuvant Intensive Therapy for HR+/ HER2-SNF4 Early Breast Cancer

HR+/HER2-breast Cancer
Fudan University

Recruiting

Adjuvant Pyrotinib and Capecitabine For HER2 Positive Micro Invasive Breast Cancer

Breast Cancer Stage I

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Recruiting

Study to Evaluate the Efficacy and Safety of SYSA1901 vs. Perjeta® of HER2-Positive Breast Cancer

HER2-positive Breast Cancer

China
Institut de cancérologie Strasbourg Europe

Not yet recruiting

Thero2-01S22 in HER2-positive Breast Cancer

HER2-positive Breast Cancer
Assiut University

Not yet recruiting

Evaluation of Targeted Axillary Lymph Node Dissection in Node Positive Breast Cancer Patients Post Neo Adjuvant Therapy

Node-positive Breast Cancer
Mansoura University

Recruiting

Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients

Breast Cancer Stage IV

Egypt
Shengjing Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of SHR-A1811 Monotherapy or Combined With Pyrotinib Maleate as Neoadjuvant Treatment in HER2-positive Breast Cancer Patients

HER2-positive Breast Cancer

China
Hunan Cancer Hospital

Recruiting

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

HR+/HER2- Breast Cancer

China
Xijing Hospital

Recruiting

Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer (ACNTBC)

Breast Cancer Stage II

China
Kliniken Essen-Mitte

Recruiting

TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes (SenTa2)

Breast Cancer | Node-positive Breast Cancer

Germany
University Health Network, Toronto

Recruiting

Kadcyla And Neratinib for Interception of HER2+ Breast Cancer With Molecular Residual Disease

Breast Cancer | HER2-positive Breast Cancer

Canada
German Breast Group
Roche Pharma AG

Recruiting

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer (GeparPiPPa)

HER2-positive Breast Cancer

Germany, Italy
Rigshospitalet, Denmark

Not yet recruiting

Effect of the App Bone@BC Version 4.0 Under the Follow-up for Patients With Early Breast Cancer

Early-stage Breast Cancer
Xijing Hospital

Not yet recruiting

RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer

Breast Cancer | HER2-positive Breast Cancer
Hospices Civils de Lyon

Not yet recruiting

NEOZOL_Follow-up Study (NEOZOL_FU)

Locally Advanced Breast Cancer

France
Blokhin's Russian Cancer Research Center

Recruiting

Analysis of Therapy Sequence in Women With HR+, HER2 - mBC in Moscow: A Multicenter Retrospective Observational Study.

Breast Cancer Stage IV

Russian Federation
Advanced Imaging Projects, LLC
University of Witwatersrand, South Africa; Postgraduate Institute of Medical...

Not yet recruiting

A Phase I/II Multicenter, Open-Label Study of Lu-177-DOTAGA-IAC, for the Treatment of Angiogenic Breast Cancer Patients. (Heroine01)

Breast Cancer Stage IV

India, South Africa
Fudan University

Recruiting

Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer (PHC-BC)

HER2-positive Breast Cancer

China
RenJi Hospital

Recruiting

Adjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer (ATP)

Locally Advanced Breast Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection

HER2-positive Breast Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Real World Study of Pyrotinib in Human Epidermal Growth Factor Receptor-2 (HER2) Positive Breast Cancer

HER2-positive Breast Cancer

China
Parc de Salut Mar
GEICAM

Recruiting

MUltimodal Targeted Axillary Surgery (MUTAS)

Node-positive Breast Cancer

Spain
Institut Paoli-Calmettes

Recruiting

Database of Data Collection (BDD-G3S)

Surgery of Breast Cancer

France
Centre Jean Perrin

Recruiting

Adapted Physical Activity for Breast Cancer HER2 Positive Patient (APACAN2)

HER2 Positive Breast Cancer

France
UNC Lineberger Comprehensive Cancer Center

Completed

Adaptation of a Values Assessment Tool

Cancer | Metastatic Breast Cancer

United States
M.D. Anderson Cancer Center
Gilead Sciences

Active, not recruiting

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

Breast Cancer

United States
University Hospital, Basel, Switzerland
ETOP IBCSG Partners Foundation; Austrian Breast Cancer Study Group

Active, not recruiting

Tailored Axillary Surgery With or Without Axillary Lymph Node Dissection Followed by Radiotherapy in Patients With Clinically Node-positive Breast Cancer (TAXIS) (TAXIS)

Node-positive Breast Cancer

United States, Latvia, Switzerland, Hungary, Austria, Germany, South Korea, Argentina, Canada, Croatia, Greece, Italy, Lithuania
Providence Health & Services
Merck Sharp & Dohme LLC; Brooklyn ImmunoTherapeutics, LLC

Active, not recruiting

Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer

Breast Cancer | Breast Neoplasms

United States
Stephen Shiao
United States Department of Defense

Active, not recruiting

Breast Cancer Study of Preoperative Pembrolizumab + Radiation

Breast Cancer

United States
Peking University

Enrolling by invitation

Multigene Risk Score Combined With Ki-67 Dynamic Assessment in Stratified Neoadjuvant Endocrine Therapy Treatment With or Without CDK4/6 Inhibitors in HR+/HER2- Breast Cancer (NeoMARS)

Breast Cancer | Early-stage Breast Cancer

China
Memorial Sloan Kettering Cancer Center

Active, not recruiting

Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy For Locally Advanced Breast Cancer

Breast Cancer | Locally Advanced Breast Cancer

United States
Deraya University

Completed

Effectiveness, Safety, and Tolerability of Anti-HER2 Drugs as Targeted Therapy for Egyptian Patients With ERBB2-Positive Breast Cancer

Breast Neoplasms | Metastatic Breast Cancer | HER2-positive Breast Cancer | Oncology

Egypt
Latin American Cooperative Oncology Group
Roche Pharma AG; Oncoclínicas

Active, not recruiting

Classifying for HER2 Dependence to De-Escalate Neoadjuvant Chemotherapy in Patients With HER2+ Early Breast Cancer Undergoing HER2 Double-Blockade (CHERRY-PICK)

Breast Cancer | HER2-positive Breast Cancer

Brazil
Ottawa Hospital Research Institute

Completed

Comparing a Single-Dose vs. Twice Yearly Zoledronate in Patients With Early Stage Breast Cancer (REaCT-ZOL) (REaCT-ZOL)

Early-stage Breast Cancer

Canada

‹
1
2
...
38
39
40
41
42
43
44
...
199
200
›

Subscribe